2026 Steven M. Opal: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	National Ranking	Publications	Citations
Immunology	100	711	406	419	121784
Medicine	102	7460	3899	450	123051

Overview

Steven M. Opal is affiliated with Brown University in the United States and conducts research predominantly in the field of Medicine. Their work spans several subfields including Epidemiology, Infectious Diseases, Immunology, Neurology, and Molecular Biology.

The scientist's research focuses on several main topics, which include:

Sepsis Diagnosis and Treatment
Immune Response and Inflammation
COVID-19 Clinical Research Studies
Long-Term Effects of COVID-19
Neonatal and Maternal Infections
Bacterial Identification and Susceptibility Testing
Antibiotics Pharmacokinetics and Efficacy

Steven M. Opal has contributed to multiple publications, with recent notable papers as follows:

"Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection" (2020), published in mBio
"Activating Immunity to Fight a Foe - A New Path" (2020), published in New England Journal of Medicine
"Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock" (2021), published in International Journal of Molecular Sciences
"Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19" (2020), published in The Lancet
"Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation" (2024), published in Journal of Clinical Medicine

The venues where Steven M. Opal frequently publishes include:

mBio
New England Journal of Medicine
International Journal of Molecular Sciences
The Lancet
Journal of Clinical Medicine

Collaborations with frequent co-authors have been an important aspect of their academic work. These co-authors include:

David S. Fedson
Ole Martin Rordam
R.A. Balk
Annette Esper
Greg S. Martin

Best Publications

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer;Clifford S. Deutschman;Christopher Warren Seymour;Manu Shankar-Hari

29560
Citations
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.

Dellinger Rp;Levy Mm;Rhodes A;Annane D

16672
Citations
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

Mitchell M. Levy;Mitchell P. Fink;John C. Marshall;Edward Abraham

14090
Citations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012

R. Phillip Dellinger;Mitchell M. Levy;Andrew Rhodes;Djillali Annane

12893
Citations
Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury

John A. Kellum;Norbert Lameire;Peter Aspelin;Rashad S. Barsoum

4021
Citations
Anti-Inflammatory Cytokines

Steven M. Opal;Vera A. DePalo

2377
Citations
High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

Brian L. Warren;Alain Eid;Pierre Singer;Subramanion S. Pillay

1843
Citations
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein

Charles J. Fisher;Jan M. Agosti;Steven M. Opal;Stephen F. Lowry

1723
Citations
Sepsis and septic shock

Richard R.S. Hotchkiss;Lyle Linc Moldawer;Steven Opal;Konrad Reinhart

1547
Citations
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Fisher Cj;Dhainaut Jf;Opal Sm;Pribble Jp

1513
Citations
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.

Christopher W. Seymour;Jason N. Kennedy;Shu Wang;Chung-Chou H. Chang

1351
Citations
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Edward Abraham;Konrad Reinhart;Steven Opal;Ignace Demeyer

1252
Citations
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

Steven M. Opal;Charles J. Fisher;Jean-Francois A. Dhainaut;Jean-Louis Vincent

1191
Citations
Sepsis: a roadmap for future research

Jonathan Cohen;Jean-Louis Vincent;Neill K J Adhikari;Flavia R Machado

1169
Citations
Sepsis definitions: time for change

Jean Louis Vincent;Steven Opal;John C Marshall;Kevin K.J. Tracey

993
Citations
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Steven M. Opal;Pierre-Francois Laterre;Bruno Francois;Steven P. LaRosa

967
Citations
Pathogenesis, treatment, and prevention of pneumococcal pneumonia.

Tom van der Poll;Steven M Opal

950
Citations
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Bita Shakoory;Joseph A. Carcillo;W. Winn Chatham;Richard L. Amdur

949
Citations
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS-Binding Protein in Patients with Severe Sepsis and Septic Shock

Steven M. Opal;Patrick J. Scannon;Jean-Louis Vincent;Mark White

798
Citations
Host-pathogen interactions in sepsis.

Tom van der Poll;Steven M Opal

746
Citations

Frequent Co-Authors

Alan S. Cross University of Maryland, Baltimore

Jean Louis Vincent Université Libre de Bruxelles

Derek C. Angus University of Pittsburgh

Jerald C. Sadoff Janssen (Belgium)

John C. Marshall University of Toronto

Kenneth H. Mayer Harvard Medical School

Tom van der Poll University of Amsterdam

Mitchell M. Levy Brown University

Edward Abraham Dragonfly Data Science (New Zealand)

Konrad Reinhart Charité - University Medicine Berlin

External Links

Personal website of Steven M. Opal

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career options. Many students consider nursing pathways, especially specialized roles like Psychiatric Mental Health Nurse Practitioners (PMHNPs). If you are looking for flexible study options, programs with nurse practitioner programs with easy admission may provide an accessible entry point to this rewarding field.

Finding the right clinical experience is crucial for success. Some of the best psychiatric mental health nurse practitioner programs online ensure excellent placement rates, helping students gain practical skills alongside theoretical knowledge.

Affordability is often a key concern. To balance cost with quality education, prospective students can explore the cheapest psychiatric nurse practitioner programs, providing budget-friendly alternatives while preparing for a successful career in healthcare.

Understanding potential earnings helps in planning a career path. Reviewing the dnp salary by specialty offers insights into the salary expectations across different states and specialties, making it easier to align educational choices with financial goals.